In conclusion, Mr. Higby said, "With more than 400 new infusion or injectable drugs in manufacturers' pipelines -- over half of which are expected to be released by 2010 -- we believe that the future of the specialty infusion business will be strong. We look forward to welcoming the Coram patients, employees and customers to Apria and realizing the combined strengths of the two businesses by offering patients the most clinically-advanced infusion and specialty pharmacy therapies and services in the country."
Apria expects Coram to generate approximately $500 million of revenue in 2008. Apria estimates that the transaction will be dilutive to net after-tax earnings by approximately $3.5 to $5.5 million in 2008, and accretive to 2009 net after-tax earnings by approximately $5.0 to $6.0 million.
Apria Healthcare was advised on the transaction by Credit Suisse Securities (USA) LLC, and Coram was advised by MTS Health Partners, L.P.
Apria provides home respiratory therapy, home infusion therapy and home medical equipment through approximately 500 locations in the United States. With over $1.5 billion in annual revenues, it is one of the nation's leading home healthcare companies. For more information, visit http://www.apria.com.
Coram is a leading provider of home infusion and specialty
pharmaceutical distribution services with more than 70 branch locations, 50
ambulatory infusion suites and centralized pharmacy distribution services
to patients in all 50 states. For more information, visit
'/>"/>
| SOURCE Apria Healthcare Group Inc. Copyright©2007 PR Newswire. All rights reserved |